EUVIMEDEUVIMED entdecken
Crossref

Timing of Off-Label Dosing of Direct Oral Anticoagulants in Three Large Health Systems

Grace C Herron, Deborah DeCamillo, Xiaowen Kong, Brian Haymart, Scott Kaatz, Stacy Ellsworth, Mona A Ali, Christopher Giuliano, James B Froehlich, Geoffrey D Barnes iD

Thrombosis and Haemostasis · 01.03.2025 · 125 (03) · 278-285

DOI: 10.1055/a-2365-8681 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.03.2025. Verfasst von Grace C Herron und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiovascular Medicine, Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan, Uni…. Hauptthemen laut MEDLINE: Off-Label Use, Atrial Fibrillation, Anticoagulants, Venous Thromboembolism. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, U.S. Public Health Service.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

While direct oral anticoagulants (DOACs) may be viewed as simpler to manage then warfarin, they present their own unique management challenges resulting in frequent off-label dosing. It is unknown to what extent off-label dosing occurs when a patient is started on a DOAC versus later in their treatment.

Objectives

We aimed to better characterize when off-label DOAC dosing is occurring and to evaluate the effectiveness of prescribing oversight using a registry-based intervention.

Methods

We evaluated data from the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) registry, a retrospective quality-improvement process using data abstractors, from 2018 to 2022 on the number of “alerts” that are generated in response to dosing deviating from the U.S. Food and Drug Administration instructions for atrial fibrillation (AF) and venous thromboembolism (VTE).

Results

Among a sample of 789 to 1,022 annual AF patients and 381 to 484 annual VTE patients prescribed a DOAC in the MAQI2 registry, off-label dosing was relatively common. Over the 5-year period (2018–2022), there were 569 alerts for AF patients and 162 alerts for VTE patients. Alerts occurred more frequently during follow-up than at the time of initial prescribing in AF patients (78.2 vs. 21.8%), but more commonly at initial prescribing in VTE patients (59.9 vs. 40.1%). After initial review by quality-improvement abstractors, 19.3% of AF alerts and 14.8% of VTE alerts resulted in contact to the prescriber. When the prescriber was contacted, it led to an intervention about 75% of the time for both populations. The most common intervention was a change in DOAC dosing.

Conclusion

This study demonstrates the benefit of DOAC prescribing oversight using a registry-based intervention to monitor for off-label dosing for the entirety of the time period a patient is prescribed DOAC, particularly for patients with AF, as off-label prescribing occurs frequently during the follow-up period.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Off-Label UseAtrial FibrillationAnticoagulantsVenous ThromboembolismFactor Xa InhibitorsHumansRetrospective StudiesAdministration, OralRegistriesFemaleMaleAgedMichiganMiddle AgedTime FactorsQuality ImprovementUnited StatesPractice Patterns, Physicians'Aged, 80 and over

Substanzen

AnticoagulantsFactor Xa Inhibitors

Autor:innen und Institutionen

  • Division of Cardiovascular Medicine, Department of Internal Medicine, Frankel Cardiovascular Center, University of Michigan, Ann Arbor, Michigan, United States.
  • Division of Hospital Medicine, Department of Medicine, Henry Ford Health, Detroit, Michigan, United States.
  • Department of Internal Medicine, Henry Ford Health, Detroit, Michigan, United States.
  • Department of Heart and Vascular Services, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, United States.
  • Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, United States.
  • Ascension St. John Hospital, Detroit, Michigan, United States.

ORCID-Profile: Geoffrey D Barnes

Förderung

  • Agency for Healthcare Research and Quality
  • U.S. Department of Health and Human Services
  • U.S. Public Health Service
  • Blue Cross Blue Shield of Michigan Foundation

Zitieren

APA

Herron, G. C., DeCamillo, D., Kong, X., Haymart, B., Kaatz, S., Ellsworth, S., Ali, M. A., Giuliano, C., Froehlich, J. B., & Barnes, G. D. (2025). Timing of Off-Label Dosing of Direct Oral Anticoagulants in Three Large Health Systems. Thrombosis and Haemostasis, 125(03), 278-285. https://doi.org/10.1055/a-2365-8681

Vancouver

Herron GC, DeCamillo D, Kong X, Haymart B, Kaatz S, Ellsworth S, et al. Timing of Off-Label Dosing of Direct Oral Anticoagulants in Three Large Health Systems. Thrombosis and Haemostasis. 2025;125(03):278-285. doi:10.1055/a-2365-8681

BibTeX
@article{Herron2025,
  author = {Herron, Grace C and DeCamillo, Deborah and Kong, Xiaowen and Haymart, Brian and Kaatz, Scott and Ellsworth, Stacy and Ali, Mona A and Giuliano, Christopher and Froehlich, James B and Barnes, Geoffrey D},
  title = {Timing of Off-Label Dosing of Direct Oral Anticoagulants in Three Large Health Systems},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {03},
  pages = {278--285},
  doi = {10.1055/a-2365-8681}
}
Kostenlos starten →